Company Overview
MindWalk Holdings Corp. operates as a bio-native AI company. The company discovers and develops biologics through HYFT Technology and LensAI platform, as well as develops AI drug discovery and biologics through ReefIQ technology. The company was formerly known as ImmunoPrecise Antibodies Ltd. and changed its name to MindWalk Holdings Corp. in September 2025. The company was incorporated in 1983 and is headquartered in Austin, Texas.
Why Investors Should Care
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Apr 2026 Revenue of $15.56M (+46.4% YoY); net profit $-13.95M.
- Trailing 12 Months Year-on-year growth — revenue +21.3%.
- 5-Year Trend Long-term compounding — revenue CAGR -9.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -9.03% |
| 1 Year: | 21.30% |
Stock Price Performance
| 1 Year: | -32.16% |
| 6 Months: | +22.73% |
| 3 Months: | -15.62% |
| 1 Month: | +3.05% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)48.08 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
CONS
- Revenue declined at -9.0% CAGR over 5 years.
- Trading 57.8% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | HYFT MindWalk Holdings Corp. PHARMA | 1.35 | -5.00 | $63.60M | 0.00% | -95.62% | -123.66% | -9.03% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jan 2025 | Apr 2025 | Jul 2025 | Oct 2025 | Jan 2026 | Apr 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 6.98M | 3.16M | 4.12M | 4.16M | 4.12M |
| Cost of Revenue | - | 2.52M | 1.63M | 1.46M | 1.69M | 1.62M |
| Gross Profit | - | 4.46M | 1.53M | 2.66M | 2.46M | 2.50M |
| Operating Expenses | - | 5.92M | 5.68M | 5.42M | 6.12M | 6.83M |
| Operating Income | - | -1.46M | -4.15M | -2.76M | -3.66M | -4.33M |
| EBITDA | - | -988.00K | -3.21M | -2.99M | -3.73M | -3.99M |
| Interest Expense | 186.00K | -1.00K | - | 0 | 0 | 0 |
| Pretax Income | - | -1.90M | -4.18M | -3.19M | -3.95M | -4.23M |
| Tax Provision | - | 261.00K | -91.00K | 25.00K | -18.00K | -367.00K |
| Net Income | - | -2.16M | -2.96M | -3.19M | -3.93M | -3.87M |
| Diluted EPS | -0.66 | - | -0.07 | -0.07 | -0.08 | -0.08 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Apr 2022 | Apr 2023 | Apr 2024 | Apr 2025 | Apr 2026 |
|---|---|---|---|---|---|
| Revenue | - | 20.66M | 10.28M | 10.63M | 15.56M |
| Cost of Revenue | - | 9.10M | 6.19M | 4.89M | 6.41M |
| Gross Profit | - | 11.56M | 4.09M | 5.73M | 9.15M |
| Operating Expenses | - | 37.17M | 21.30M | 21.32M | 24.05M |
| Operating Income | - | -25.61M | -17.21M | -15.59M | -14.90M |
| EBITDA | - | -21.04M | -26.41M | -32.21M | -13.95M |
| Interest Expense | - | 30.00K | 19.00K | 306.00K | 0 |
| Pretax Income | - | -27.75M | -32.16M | -37.63M | -15.55M |
| Tax Provision | - | -1.19M | -2.86M | -4.48M | -450.00K |
| Net Income | - | -26.56M | -26.11M | -30.23M | -13.95M |
| Diluted EPS | - | -1.07 | -1.02 | -0.90 | -0.31 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Apr 2022 | Apr 2023 | Apr 2024 | Apr 2025 | Apr 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 77.81M | 59.99M | 44.44M | 21.38M |
| Current Assets | - | 16.79M | 11.49M | 18.75M | 16.22M |
| Cash & Equivalents | - | 8.28M | 3.46M | 10.66M | 11.35M |
| Inventory | - | 2.06M | 2.14M | 2.10M | 492.00K |
| Receivables | - | 3.25M | 3.79M | 4.12M | 2.53M |
| Total Liabilities | - | 20.01M | 24.31M | 20.82M | 9.63M |
| Current Liabilities | - | 5.92M | 8.12M | 9.01M | 5.79M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 7.27M | 13.68M | 13.40M | 3.53M |
| Total Equity | - | 57.80M | 35.68M | 23.63M | 11.75M |
| Shares Outstanding | - | 25.05M | 26.94M | 46.15M | 46.71M |
Cash Flows (Annual)
Figures in USD.
| Metric | Apr 2022 | Apr 2023 | Apr 2024 | Apr 2025 | Apr 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -19.83M | -3.18M | -6.41M | -12.46M |
| Investing Cash Flow | - | -1.97M | -1.56M | -799.00K | 13.54M |
| Financing Cash Flow | - | -621.00K | 1.02M | 14.89M | 115.00K |
| Capital Expenditure | - | -1.50M | -1.40M | -799.00K | -398.00K |
| Free Cash Flow | - | -21.33M | -4.58M | -7.21M | -12.86M |
| Net Change in Cash | - | -22.42M | -3.73M | 7.68M | 1.20M |
Ratios (Annual)
Figures in %.
| Metric | Apr 2022 | Apr 2023 | Apr 2024 | Apr 2025 | Apr 2026 |
|---|---|---|---|---|---|
| Gross Margin % | - | 56.0% | 39.8% | 53.9% | 58.8% |
| Operating Margin % | - | -123.9% | -167.4% | -146.7% | -95.8% |
| Net Margin % | - | -128.5% | -254.1% | -284.5% | -89.7% |
| ROE % | - | -45.9% | -73.2% | -128.0% | -118.7% |
| ROCE % | - | -35.6% | -33.2% | -44.0% | -95.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Ingalls & Snyder LLC | 6.50% | 3.04M | $4.13M |
| 2 | Susquehanna International Group, LLP | 1.11% | 520.77K | $708.25K |
| 3 | Renaissance Technologies, LLC | 0.46% | 213.38K | $290.20K |
| 4 | Blackrock Inc. | 0.33% | 154.41K | $210.00K |
| 5 | Marshall Wace LLP | 0.29% | 135.97K | $184.91K |
| 6 | Bank of Montreal /CAN/ | 0.17% | 77.95K | $106.01K |
| 7 | Allianz Asset Management GmbH | 0.07% | 35.00K | $47.60K |
| 8 | GSA Capital Partners LLP | 0.07% | 34.52K | $46.95K |
| 9 | Gradient Capital Advisors, LLC | 0.06% | 26.55K | $36.11K |
| 10 | Geode Capital Management, LLC | 0.05% | 25.49K | $34.67K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for HYFT
First-quarter results are scheduled for Sept. 14 from MindWalk - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxPTEluT0VMdUk5eHNNZkVpTTYyalV3aXZ2U2tqRlppSlJnQkw1TnZ5cEhkTGp2ZDhLem1jeEtSb0NZVUdCaVN6SHJxYnRJLUpaMXc4c2VEcWFOYW9Fb0JKelE2dEVnWUo5WmUwaHgwRlhXR1ZCUFk3RlhwdXMwc0dPdzF1UWsxbkU5QVJBZT…
MindWalk (HYFT) schedules Sept. 14 call on Q1 2027 results - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxQR3dBd3ZmOUVrVVBCblFhbFlNNW9NZ2UyWnVlbW9SUmozR05XOW1EZTB2SGs5TDRhLXl1RmoxSkkxdTc1Vk04QzUwMjlfemVERGNpZ0xxaUQyeV9CRk1tbkxwVHNuOHVvV0NhYnJWZmhXaDVHbzNpZm5Jb28wOEc2STFscDNPTnJlMjlpY2…
MindWalk Holdings Corp. (HYFT) Reports Q4 Loss, Misses Revenue Estimates - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxNN0xDUVhjWmJzVzc0WWFRTmtEZmhCTmE0UG4zNG5tQk40djgwQlRyQkFwNzBheUo0VXpHSTJkcThlSi12U1RVbjNkeDRYUWtjeTdLaVpTdzlVVVUtMXE4MG1ya0NxTHAzSFF2LVNmQ2pvaGZqUzVaNm9HZlFXd0ZaSVdkRzIxWlpKYUE4Yk…
HYFT News | MINDWALK HOLDINGS CORP (NASDAQ:HYFT) - ChartMill
<a href="https://news.google.com/rss/articles/CBMiW0FVX3lxTE5EWlk0WU8xYXdZNTUweGFQWUFaQVV3LVNZZUJ4WXNNRTNQcjRER1FVVTJrSVJJS2hPSUV3RmtZY2RxVmYyTnpYSzB3RlVzelMxenBGdDhxcnphNUk?oc=5" target="_blank">HYFT News | MINDWALK HOLDINGS CORP (NASDAQ:H…
MINDWALK HOLDINGS ($HYFT) Releases Q4 2026 Earnings | HYFT Stock News - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxNSUZicUZycGttc1F3TWV3UExTLVNSR3hKenJCUDk1RGl2dnJFRzVOMW1PcWlKWGt3VFV3VS1oamFBajBGTi12V29VWTZQTThfa0ZUZHlSTUhqeHkzMW5zRmhhVFBSczBYNjhVd0o2dlBsSEpBbnl2RTRpeF9GOXBSOVVRemJnSVM2T2FYUD…
HYFT Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE02UFZiMmw4RXBIVVh0UnRrcDdubXNJdVRpbDNsY3pRbmZBbDEwSU43MjFUTnRybmhDTElnUWR4Vjlsemh0MzlXckpvaVBBWkV1NzQyZ1VZNnRmRHdOajhJSmpOa2VKbXlFSDBMTXQxNmlhVmw0ZzdYWDJn?oc=5" target="_blank">HYF…
HYFT — Frequently Asked Questions
What is the current share price of MindWalk Holdings Corp. (HYFT)?
As of 2026-09-19 21:16 PDT, MindWalk Holdings Corp. (HYFT) trades at $1.35 on NasdaqCM. Its 52-week range is $1.02 to $3.20.
What is the market capitalisation of HYFT?
MindWalk Holdings Corp. (HYFT) has a market capitalisation of $63.60M on NasdaqCM.
What is the P/E ratio of HYFT?
HYFT trades at a trailing price-to-earnings (P/E) ratio of -5.00. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 7.47.
What is the return on equity (ROE) of HYFT?
HYFT has a return on equity (ROE) of -123.66%. Its return on capital employed (ROCE) is -95.62%.
Is HYFT a good stock to buy?
This page provides a data-driven analysis of MindWalk Holdings Corp. (HYFT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.